Breakthroughs for Pharmaceutical Organizations

Transcription

1 Breakthroughs for Pharmaceutical Organizations

2 Strong Incentives to Make R&D More Effective and Efficient Challenges with re-use of patient level data Data gaps Data quality Semantics Privacy Missing data elements (e.g. outcomes) RTC s require details that may not be routinely collected Coding often only at first level (e.g. ICD-9) therefore missing granularity 80% of info stored as unstructured data Longitudinality Coding for administrative reasons (up-down coding) Coding often months after patient encounter Data provenance who entered the data? Many standards many versions Complex care many HCP s involved many hand-overs Need to pool data cross sites and cross different countries Pharma focused on CDISC Clearly a top priority Different interpretations by country, by region-complex Trust 2 The Pharmaceutical Industry in figures. Key data 2012 efpia report

3 Harvesting Value from Unstructured Data Direct impact on data gaps and quality Improving the quality of the prescreening of the patient selection before you start clinical trials Improving the quality and quantity of outcome of the patient selection Improving the quality and completeness of the data And thus a direct impact the time cycle of clinical trials 3

4 Harvesting Value from Our Interoperability Platform Direct impact on data semantics and privacy Flexible extendable interoperability platform (local, regional, national wide) Linking the healthcare standards with the LF standards (no need to re-input the data) Complete secure environment used in combination with trusted third-party providers And thus a direct impact again on the time cycle of clinical trials 4

5 Harvesting Value from a Real Healthcare Partner Direct impact on your understanding and availability of healthcare data Our extended references in the healthcare arena Our expertise in storing and sharing clinical data Our partnering mind set Our pragmatic approach to get quickly to your solution And thus a direct impact on your go-to-market time line 5

6 Examples of the InterSystems Breakthrough in Action Breakthrough Population Screening 6

7 Breakthroughs for Pharmaceutical Organizations

8 Identifying Hepatitis C At Risk Patients HCV Risk Group Drivers Injecting Drug User (IDU) HIV Country of origin: HCV prevalence > 2% High ethnic mix area LFT: ALT more the Transfusion before 1992 Piercing Acupuncture Tattoo Men having sex with men (MSM) Household & sex partners of Hep carriers Prison stay Positive Risk Alert Alert and outcome score Clinical support Guidance on additional questions Testing recommendation Links to knowledge base Patient Database Algorithm Criteria Risk Indicator Flag Hep C Test 8

9 Use Cases Return

10 University Hospital Antwerp Patient selection (for clinical trials) Some criteria can be found in electronic patient record Most criteria can only be found in notes Use set analysis to select patients in unstructured patient notes Compare selected patients with manual effort and standard search tools like Apache s Lucene 10

11 University Hospital Antwerp 11

12 Use Cases Return

13 The iknow Clinical Information Breakthrough Applications DeepSee Analytics Third-Party Tools Cross standards Render unstructured data meaningful and usable Transaction speed data performance Access, aggregate, normalize data From small (1 hospital to internationally extendable) InterSystems Breakthrough Platform The gold standard healthcare technology platform 13

14 The InterSystems Clinical Information Breakthrough FAQ Is it possible to map with internationally standards (ex: HL7 with CDISK)? What about semantic interoperability (ex: LOINC, SNOMED, )? Are you talking to the CRO organizations? What would be nice is to have one global or national Market Place where we can buy clinical information Can you introduce us to your customers in South Africa, Brazil, Chile, Scotland, Sweden, Are you aware of the European funded cooperational projects as IMI? 14

15 Breakthroughs for Pharmaceutical Organizations